These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 23938351)
1. Neuronal expression of familial Parkinson's disease A53T α-synuclein causes early motor impairment, reduced anxiety and potential sleep disturbances in mice. Rothman SM; Griffioen KJ; Vranis N; Ladenheim B; Cong WN; Cadet JL; Haran J; Martin B; Mattson MP J Parkinsons Dis; 2013; 3(2):215-29. PubMed ID: 23938351 [TBL] [Abstract][Full Text] [Related]
2. Mice expressing the A53T mutant form of human alpha-synuclein exhibit hyperactivity and reduced anxiety-like behavior. Graham DR; Sidhu A J Neurosci Res; 2010 Jun; 88(8):1777-83. PubMed ID: 20077428 [TBL] [Abstract][Full Text] [Related]
3. Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model. Wang W; Song N; Jia F; Tang T; Bao W; Zuo C; Xie J; Jiang H Neurochem Int; 2018 Mar; 114():71-79. PubMed ID: 29355568 [TBL] [Abstract][Full Text] [Related]
4. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice. Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282 [TBL] [Abstract][Full Text] [Related]
5. Alpha-synuclein interferes with cAMP/PKA-dependent upregulation of dopamine β-hydroxylase and is associated with abnormal adaptive responses to immobilization stress. Kim S; Park JM; Moon J; Choi HJ Exp Neurol; 2014 Feb; 252():63-74. PubMed ID: 24252179 [TBL] [Abstract][Full Text] [Related]
6. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model. Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026 [TBL] [Abstract][Full Text] [Related]
7. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice. Unger EL; Eve DJ; Perez XA; Reichenbach DK; Xu Y; Lee MK; Andrews AM Neurobiol Dis; 2006 Feb; 21(2):431-43. PubMed ID: 16230020 [TBL] [Abstract][Full Text] [Related]
8. Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function. Oaks AW; Frankfurt M; Finkelstein DI; Sidhu A PLoS One; 2013; 8(4):e60378. PubMed ID: 23560093 [TBL] [Abstract][Full Text] [Related]
9. Generation of a alpha-synuclein-based rat model of Parkinson's disease. Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315 [TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. George S; van den Buuse M; San Mok S; Masters CL; Li QX; Culvenor JG Exp Neurol; 2008 Apr; 210(2):788-92. PubMed ID: 18295208 [TBL] [Abstract][Full Text] [Related]
11. Differential effects of overexpression of wild-type and mutant human alpha-synuclein on MPP+-induced neurotoxicity in PC12 cells. Qian JJ; Cheng YB; Yang YP; Mao CJ; Qin ZH; Li K; Liu CF Neurosci Lett; 2008 Apr; 435(2):142-6. PubMed ID: 18342443 [TBL] [Abstract][Full Text] [Related]
13. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease. Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974 [TBL] [Abstract][Full Text] [Related]
14. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice. Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572 [TBL] [Abstract][Full Text] [Related]
15. Chronic mild stress accelerates the progression of Parkinson's disease in A53T α-synuclein transgenic mice. Wu Q; Yang X; Zhang Y; Zhang L; Feng L Exp Neurol; 2016 Nov; 285(Pt A):61-71. PubMed ID: 27637804 [TBL] [Abstract][Full Text] [Related]
16. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study. Wilson H; Dervenoulas G; Pagano G; Koros C; Yousaf T; Picillo M; Polychronis S; Simitsi A; Giordano B; Chappell Z; Corcoran B; Stamelou M; Gunn RN; Pellecchia MT; Rabiner EA; Barone P; Stefanis L; Politis M Lancet Neurol; 2019 Aug; 18(8):748-759. PubMed ID: 31229470 [TBL] [Abstract][Full Text] [Related]
17. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758 [TBL] [Abstract][Full Text] [Related]
18. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia. Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690 [TBL] [Abstract][Full Text] [Related]
19. Early Parkinson's disease symptoms in α-synuclein transgenic monkeys. Niu Y; Guo X; Chen Y; Wang CE; Gao J; Yang W; Kang Y; Si W; Wang H; Yang SH; Li S; Ji W; Li XJ Hum Mol Genet; 2015 Apr; 24(8):2308-17. PubMed ID: 25552648 [TBL] [Abstract][Full Text] [Related]